We are live on ! Find out more
OC

Oppenheimer & Co Portfolio holdings

AUM $8.21B
1-Year Est. Return 28.81%
This Fund
S&P 500
This Quarter Est. Return
+2.6%
1 Year Est. Return
+28.81%
3 Year Est. Return
+92.54%
5 Year Est. Return
+114.67%
10 Year Est. Return
+429.8%
AUM
$3.34B
AUM Growth
+$209M
Cap. Flow
+$157M
Cap. Flow %
4.72%
Top 10 Hldgs %
12.01%
Holding
1,564
New
189
Increased
576
Reduced
529
Closed
163

Sector Composition

Rank Sector Weight
1 Energy 11.94%
2 Healthcare 10.62%
3 Industrials 9.8%
4 Technology 9.43%
5 Financials 9.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NZF icon
1251
Nuveen Municipal Credit Income Fund
NZF
$2.41B
$194K 0.01%
14,819
-119
-0.8% -$1.53K
NOAH
1252
Noah Holdings
NOAH
$583M
$193K 0.01%
+13,364
New +$203K
BBF
1253
DELISTED
BlackRock Municipal Income Investment Trust
BBF
$193K 0.01%
14,500
-600
-4% -$7.82K
RXII
1254
DELISTED
GALENA BIOPHARMA INC COM
RXII
$192K 0.01%
76,699
-8,101
-10% -$20.3K
PWE
1255
DELISTED
Penn West Energy Petroleum Ltd
PWE
$190K 0.01%
22,687
-923
-4% -$7.46K
HBAN icon
1256
Huntington Bancshares
HBAN
$34.5B
$189K 0.01%
18,917
+1,375
+8% +$13.1K
ZNGA
1257
DELISTED
ZYNGA INC. CL A COMMON
ZNGA
$189K 0.01%
43,985
-300
-0.7% -$1.38K
RSOL
1258
DELISTED
REAL GOODS SOLAR, INC. CL A COM
RSOL
$189K 0.01%
+46,316
New +$181K
GEQ
1259
DELISTED
Gugnheim Eql Wght Enh Eqty In Fd
GEQ
$188K 0.01%
10,000
CEVA icon
1260
CEVA Inc
CEVA
$916M
$186K 0.01%
10,600
-1,100
-9% -$18.9K
PLX icon
1261
Protalix BioTherapeutics
PLX
$183M
$186K 0.01%
4,050
+965
+31% +$45K
G icon
1262
Genpact
G
$5.99B
$185K 0.01%
+10,612
New +$179K
VLY icon
1263
Valley National Bancorp
VLY
$7.92B
$183K 0.01%
17,589
+4,600
+35% +$46.1K
EMD
1264
DELISTED
Western Asset Emerging Markets
EMD
$181K 0.01%
14,664
MUE
1265
DELISTED
BlackRock MuniHoldings Quality Fund II
MUE
$180K 0.01%
+14,143
New +$178K
WU icon
1266
Western Union
WU
$2.4B
$179K 0.01%
10,950
-1,111
-9% -$18.1K
GRPN icon
1267
Groupon
GRPN
$1.06B
$178K 0.01%
+1,137
New +$221K
IDE
1268
Voya Infrastructure, Industrials and Materials Fund
IDE
$196M
$178K 0.01%
+10,150
New +$172K
NZH
1269
DELISTED
Nuveen Calif Div
NZH
$176K 0.01%
14,439
-1,547
-10% -$18.5K
LPSN icon
1270
LivePerson
LPSN
$22M
$173K 0.01%
957
-96
-9% -$19.2K
WLT
1271
DELISTED
WALTER ENERGY INC COM STK (DE)
WLT
$173K 0.01%
22,905
-4,870
-18% -$53.6K
ALLT icon
1272
Allot
ALLT
$367M
$170K 0.01%
12,640
-2,003
-14% -$31.6K
BYM
1273
DELISTED
BlackRock Municipal Income Quality Trust
BYM
$169K 0.01%
12,425
-5,139
-29% -$68.9K
MYF
1274
DELISTED
Blackrock Muni Yield Investment Fund, Inc.
MYF
$169K 0.01%
11,900
-200
-2% -$2.81K
SPLS
1275
DELISTED
Staples Inc
SPLS
$169K 0.01%
14,932
-15,721
-51% -$205K

Similar funds

Oppenheimer & Co's Q1 2014 Portfolio in Review

As of Q1 2014, Oppenheimer & Co held 1,564 positions worth $3.34B, up 6.7% from $3.13B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Oppenheimer & Co deployed $157M of net new capital in Q1 2014, opening 189 new positions and adding to 576 existing holdings. Its largest new stake was Vanguard Morningstar Total Stock Market ETF: 169,083 shares worth $16.5M.

By sector, the portfolio is most concentrated in Energy at 12% of assets, down from 12% a quarter earlier, followed by Healthcare and Industrials.

On the sell side, the largest reduction was Vanguard Dividend Appreciation ETF, an estimated $7.79M trimmed.

  • Oppenheimer & Co's largest Q1 2014 buy was Vanguard Morningstar Total Stock Market ETF: 169,083 shares worth $16.5M.
  • Oppenheimer & Co added most to Monsanto Co in Q1 2014, an estimated $30M increase.
  • Oppenheimer & Co's biggest Q1 2014 reduction was Vanguard Dividend Appreciation ETF, cutting an estimated $7.79M.
  • Oppenheimer & Co fully exited TetraLogic Pharmaceuticals Corporation in Q1 2014, selling an estimated $10.2M.
  • Oppenheimer & Co's ten largest holdings make up 12% of its $3.34B portfolio in Q1 2014.
  • Oppenheimer & Co opened 189 new positions and closed 163 in Q1 2014.
  • Oppenheimer & Co's portfolio value rose 6.7% quarter-over-quarter to $3.34B.

Based on Oppenheimer & Co's 13F filing for Q1 2014, filed 9 May 2014.